Current report filing

Document and Entity Information

v3.23.2
Document and Entity Information
Jun. 29, 2023
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag true
Entity Central Index Key 0001780097
Document Type 8-K/A
Document Period End Date Jun. 29, 2023
Entity Registrant Name Baudax Bio, Inc.
Entity Incorporation State Country Code PA
Entity File Number 001-39101
Entity Tax Identification Number 47-4639500
Entity Address, Address Line One 490 Lapp Road
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code (484)
Local Phone Number 395-2470
Written Communications false
Soliciting Material true
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01
Trading Symbol BXRX
Entity Emerging Growth Company true
Entity Ex Transition Period true
Amendment Description On July 5, 2023, Baudax Bio, Inc., a Pennsylvania corporation (the “Company”), filed a Current Report on Form 8-K announcing that on June 29, 2023 (the “Effective Date”), the Company had acquired TeraImmune, Inc., a Delaware corporation (“TeraImmune”) pursuant to that certain Agreement and Plan of Merger, dated as of the Effective Date (the “Merger Agreement”) by and among the Company, Bounce Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), Bounce Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and TeraImmune. This Current Report on Form 8-K/A amends and supplements the Current Report on Form 8-K filed on July 5, 2023 (the “July 2023 Form 8-K”) to provide the pro forma information required by Items 9.01(a) and 9.01(b) of Form 8-K. The text of the July 2023 Form 8-K is incorporated herein by reference. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the July 2023 Form 8-K.